18F-FDG PET in the management of endometrial cancer

[1]  P. Grigsby,et al.  Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. , 2004, Gynecologic oncology.

[2]  G. Scambia,et al.  Local-regional staging of endometrial carcinoma: role of MR imaging in surgical planning. , 2004, Radiology.

[3]  T. Yen,et al.  Restaging of recurrent cervical carcinoma with dual‐phase [18F]fluoro‐2‐deoxy‐D‐glucose positron emission tomography , 2004, Cancer.

[4]  D. Grisaru,et al.  Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  T. Yen,et al.  Value of dual-phase 2-fluoro-2-deoxy-d-glucose positron emission tomography in cervical cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  E. Yoshikawa,et al.  Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  K. Togashi,et al.  Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer , 2003, Annals of nuclear medicine.

[8]  S. Lentz.  Endometrial carcinoma diagnosed by positron emission tomography: a case report. , 2002, Gynecologic oncology.

[9]  R. Hustinx,et al.  Usefulness of 18F-FDG PET in the post-therapy surveillance of endometrial carcinoma , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  R. Berkowitz,et al.  Advances in the management of endometrial adenocarcinoma. A review. , 2002, The Journal of reproductive medicine.

[11]  B. Nowak,et al.  2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. , 2001, Gynecologic oncology.

[12]  M. J. Webb,et al.  Role of wide/radical hysterectomy and pelvic lymph node dissection in endometrial cancer with cervical involvement. , 2001, Gynecologic oncology.

[13]  F Dehdashti,et al.  Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  H M Bonél,et al.  Prediction of deep myometrial invasion in patients with endometrial cancer: clinical utility of contrast-enhanced MR imaging-a meta-analysis and Bayesian analysis. , 2000, Radiology.

[15]  D. Dotters,et al.  Preoperative CA 125 in endometrial cancer: is it useful? , 2000, American journal of obstetrics and gynecology.

[16]  K. Ng,et al.  Radical resection and intraoperative radiotherapy for a recurrent endometrial cancer after prolonged remission following aggressive salvage therapy: case report. , 1999, Changgeng yi xue za zhi.

[17]  E. Venkatraman,et al.  Pelvic exenteration for recurrent endometrial cancer. , 1999, Gynecologic oncology.

[18]  S. Broste,et al.  Surgery Without Radiotherapy for Primary Treatment of Endometrial Cancer , 1998, Obstetrics and gynecology.

[19]  M. Dowsett,et al.  Long-term follow-up of gonadotrophin-releasing hormone analog treatment for recurrent endometrial cancer. , 1996, Gynecologic oncology.

[20]  R. Alvarez,et al.  Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. , 1996, Gynecologic oncology.

[21]  K. Greven,et al.  Prognostic factors and treatment outcome for patients with locally recurrent endometrial cancer , 1994, Cancer.

[22]  C. Morrow,et al.  Relationship between surgical‐pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group study , 1991, Gynecologic oncology.

[23]  B. Gross,et al.  Upper abdominal lymph nodes: criteria for normal size determined with CT. , 1991, Radiology.

[24]  B. Cheson,et al.  Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  W. Mann,et al.  The value of preoperative serum CA 125 levels in patients with a pelvic mass. , 1988, American journal of obstetrics and gynecology.

[26]  H. D. de Bruijn,et al.  CA 125: A useful marker in endometrial carcinoma , 1987, American journal of obstetrics and gynecology.

[27]  S. Yasuda,et al.  F-18 FDG uptake in endometrial cancer. , 2001, Clinical nuclear medicine.

[28]  L. Adler,et al.  Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  V. Abeler,et al.  Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients. , 1984, Gynecologic oncology.